Deutsche Boerse in Deal with Six Group, Novartis to Acquire Spinifex

Nigel Thomas
29 Jun, 2015
New York City

Deutsche Boerse is in talks with Six Group to acquire the remaining stakes in Stoxx and Indexium for 650 million Swiss francs. BMW in a consortium plans to bid for Australia and New Zealand Banking Group''s car and equipment loan business.

[R]4:00 PM Frankfurt – Deutsche Boerse is in talks with Six Group to acquire the remaining stakes in Stoxx and Indexium for 650 million Swiss francs. BMW in a consortium plans to bid for Australia and New Zealand Banking Group''s car and equipment loan business.[/R]

In London trading, FTSE 100 index slumped 1.4% or 95.38 to 6,658.25 and in Frankfurt the DAX index dropped 2.7% or 310.96 to 11,183.08.

In Paris, CAC 40 index declined 3% or 151.94 to 4,808.09.

Bayerische Motoren Werke AG declined 3.8% to €99.58 after Reuters said the Germany-based auto maker and Australia-based Macquarie Group Ltd and the U.S.-based private equity firms are planning to to bid for Australia and New Zealand Banking Group''s car and equipment loan business of about more than $6 billion.

Deutsche Boerse AG dropped 2.4% to €75.23 after the Germany-based exchange operator is in talks with Switzerland-based Six Group to buy the remaining stakes in the equity index joint ventures Stoxx AG and Indexium AG for about 650 million Swiss francs or $692 million.

Deutsche Boerse already acquired 50.1% in STOXX AG and 49.9% of Indexium AG.

Eurofins Scientific SE slumped 3.8% to €266.30 after the Luxembourg-based food and pharmaceutical products testing laboratory operator signed an agreement to acquire 75% stake in Emory Genetics Laboratory, a testing laboratory for the rare genetic disorders from Emory University for about $40 million in cash.

Lamprell Plc rose 0.2% to 152.25 pence after the U.K.-based offshore and onshore oil and gas services provider said it is on track to deliver full-year results in line with expectations and continued to excellent performance despite challenging market conditions.

Novartis AG fell 0.6% to 92.70 Swiss francs after the Switzerland-based drug-maker agreed to acquire the U.S.-Australian privately-held biotech company Spinifex Pharmaceuticals Inc, a developer of treatments for neuropathic pain, for about $200 million.

The transaction is expected to close in the second-half of this year.